Clinical value of the guanase screening test in donor blood for prevention of posttransfusional non‐A, non‐B hepatitis
Clinical value of the guanase screening test in donor blood for prevention of posttransfusional non‐A, non‐B hepatitis
复制标题
供血鸟苷酶筛查试验预防输血后非甲非乙型肝炎的临床价值
DOI：
10.1002/hep.1840080233
复制
发表时间：
1988
期刊：
影响因子：
13.5
通讯作者：
H. Mori
中科院分区：
文献类型：
--
作者：
S. Ito;Y. Tsuji;Naoyuki Kitagawa;Ishihara Akihiko;J. Syundo;Y. Tamura;S. Kishi;H. Mori
我们采用自动化方法测量供体血液中的鸟苷酶，并在排除具有高鸟苷酶活性的供体血液时检查输血后非甲非B型肝炎的发生率。2，826个单位中有67个（2.4%）被排除在输血之外，因为它们的鸟苷酶活性高于1.71单位/L。在112例受者中，8例（7%）发生输血后非甲非B型肝炎。采用胍酶筛查试验前输血后非甲非B型肝炎的发生率为17%，采用后为7%。因此，采用该筛选试验后，输血后非甲非B型肝炎的发生率显著降低。
We adopted an automated method for measuring guanase in donor blood and examined the incidence of posttransfusional non‐A, non‐B hepatitis when donor blood with high guanase activities was excluded. Sixty‐seven (2.4%) of 2,826 units were excluded from use in transfusion because they had guanase activities above 1.71 units per liter. Of 112 recipients, 8 (7%) developed posttransfusional non‐A, non‐B hepatitis. The incidence of posttransfusional non‐A, non‐B hepatitis was 17% before adoption of the guanase screening test and 7% after its adoption. Thus, the incidence of posttransfusional non‐A, non‐B hepatitis was significantly decreased after adoption of this screening test.